Indication
Chronic eosinophilic leukemia
Chronic eosinophilic leukemia is a rare myeloproliferative neoplasm characterized by the autonomous, clonal overproduction of eosinophils within the bone marrow, peripheral blood, and tissues. Read more about Chronic eosinophilic leukemia
28 drugs 27 manufacturers
Drugs that treat it
Common Chronic eosinophilic leukemia therapies.
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic eosinophilic leukemia is a rare myeloproliferative neoplasm characterized by the autonomous, clonal overproduction of eosinophils within the bone marrow, peripheral blood, and tissues.
Primarily affecting adults, the disease involves persistent hypereosinophilia accompanied by cytogenetic abnormalities, somatic driver mutations, or elevated blast counts, while excluding reactive causes and distinct myeloid neoplasms defined by rearrangements such as *PDGFRA*, *PDGFRB*, *FGFR1*, or *PCM1::JAK2*.
Widespread infiltration of tissues by mature and immature eosinophils releases cytotoxic granules, commonly causing organ dysfunction and damage across the cardiovascular system, central nervous system, lungs, skin, and gastrointestinal tract.
- cancer.gov
Chronic eosinophilic leukemia is a rare myeloproliferative neoplasm characterized by the autonomous, clonal overproduction of eosinophils within the bone marrow, peripheral blood, and tissues
- medlineplus.gov
Primarily affecting adults, the disease involves persistent hypereosinophilia accompanied by cytogenetic abnormalities, somatic driver mutations, or elevated blast counts, while excluding reactive causes and distinct myeloid neoplasms defined by rearrangements such as *PDGFRA*, *PDGFRB*, *FGFR1*, or *PCM1::JAK2*
- hematology.org
Primarily affecting adults, the disease involves persistent hypereosinophilia accompanied by cytogenetic abnormalities, somatic driver mutations, or elevated blast counts, while excluding reactive causes and distinct myeloid neoplasms defined by rearrangements such as *PDGFRA*, *PDGFRB*, *FGFR1*, or *PCM1::JAK2* Widespread infiltration of tissues by mature and immature eosinophils releases cytotoxic granules, commonly causing organ dysfunction and damage across the cardiovascular system, central...
- youtube.com
Widespread infiltration of tissues by mature and immature eosinophils releases cytotoxic granules, commonly causing organ dysfunction and damage across the cardiovascular system, central nervous system, lungs, skin, and gastrointestinal tract
Personalize your experience
Follow Chronic eosinophilic leukemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.